Person:
GÜNEŞ, BEGÜM

Loading...
Profile Picture
Email Address
Birth Date
Research Projects
Organizational Units
Organizational Unit
Job Title
Last Name
GÜNEŞ
First Name
BEGÜM
Name

Search Results

Now showing 1 - 4 of 4
  • Publication
    Metadata only
    Importance of Follow Up in Determining PSA Prevalence of PSA in Turkish Psoriasis Patients
    (2019-06-15T00:00:00Z) GÜNEŞ, BEGÜM; GÜLCAN, ALİYE SEVDEM; DİZMAN, DİDEM; BAHALI, ANIL GÜLSEL; AKASLAN, TAHSİN ÇAĞDAŞ; REZVANİ, AYLİN; ONSUN, NAHİDE; GÜNEŞ, BEGÜM; GÜLCAN, ALİYE SEVDEM; BAHALI, ANIL GÜLSEL; AKASLAN, TAHSİN ÇAĞDAŞ
  • Publication
    Metadata only
    Bezmialem Vakıf Üniversitesi’nin 15 yıllık etanercept deneyimi ve etanercept sürdürülebilirliği
    (2020-12-04T00:00:00Z) Onsun, Nahide; Güneş, Begüm; Yabacı, Ayşegül; ONSUN, NAHIDE; GÜNEŞ, BEGÜM; YABACI TAK, AYŞEGÜL
  • Publication
    Metadata only
    Demographic characteristics, treatment, and outcome of patients with Kaposi sarcoma: Ten-year follow-up results of a single center
    (2021-09-01T00:00:00Z) GÜNEŞ, BEGÜM; MERT, Ömer; ONSUN, Nahide; GÜNEŞ, BEGÜM; MERT, ÖMER; ONSUN, NAHIDE
    Background Clinical features, types of Kaposi sarcoma, and treatment outcomes have not been well-defined in Turkey. In this study, we reviewed records of the patients who had been diagnosed with Kaposi sarcoma in the last decade in a single center and evaluated treatment results. Methods Medical records of the Kaposi sarcoma patients seen in the last decade in a single tertiary center were evaluated in detail. Results A total of 27 patients were identified; 18 patients had been checked for HHV8; and 16 of those patients were positive for HHV8. One patient was positive for HIV. Two patients having mycosis fungoides and myasthenia graves developed iatrogenic KS after immunosuppressive treatments. Interferon alpha was used in 21 patients; 8 patients achieved complete response; and 11 patients achieved a partial response. No serious side effects were observed. Systemic involvement did not develop in any patients except lymph node involvement in a patient with widespread skin lesions.
  • Publication
    Metadata only
    A multicentre prospective analysis of the incidence of pemphigoid diseases in Turkey
    (2021-10-01T00:00:00Z) DURDU, MURAT; Bozca, Burcin Cansu; ENLİ, SERVİNAZ; Yazici Ozgen, Zuleyha; YAYLI, SAVAŞ; AKTAN, ŞEBNEM; MUTLU, DERYA; ERTURAN, İjlal; AYVAZ ÇELİK, Havva Hilal; MELİKOĞLU, Mehmet; PALA, Erdal; Gursel Urun, Yildiz; HARMAN, MEHMET; BOZKURT ŞAVK, EKİN; Isik, Selin; Duygulu, Seniz; Imren, Isil Gogem; FETTAHLIOĞLU KARAMAN, BİLGE; KAYA ERDOĞAN, HİLAL; KILIÇ, ARZU; Ozcelik, Sinan; Inan, Kiymet; Yilmaz, Mustafa Anil; Sanli, Hatice Erdi; Kalay Yildizhan, Incilay; MÜLAYİM, MEHMET KAMİL; Cicek, Demet; Demir, Betul; YASAK GÜNER, RUKİYE; BAYKAL SELÇUK, LEYLA; GÜNDÜZ, KAMER; DAYE, MUNİSE; BORLU, MURAT; ÖKSÜM SOLAK, EDA; DİZMAN, DİDEM; GÜNEŞ, BEGÜM; Ozkur, Ezgi; Polat, Mualla; Eskiocak, Ali Haydar; UZUN, SONER; DİZMAN, DİDEM; GÜNEŞ, BEGÜM
    Background The differentiation between the pemphigoid diseases is essential for treatment and prognosis. In Turkey, data on the incidence of these diseases are insufficient. Our aim in this study is to determine the incidence, demographics and clinical characteristics associated with diseases of the pemphigoid group. Methods We prospectively analysed 295 patients with pemphigoid who visited dermatology clinics of tertiary referral hospitals in 12 different regions of Turkey within a year. The diagnosis was based on clinical, histopathological, direct immunofluorescence (DIF) and serological (multivariant enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence and mosaic-based BIOCHIP) examinations. Clinical and demographic findings, aetiological factors and concomitant diseases observed in the patients were recorded. Results A total of 295 (female/male ratio: 1.7/1) patients with pemphigoid were diagnosed in 1-year period. The overall incidence rate of pemphigoid diseases was found to be 3.55 cases per million-years. The ratio of pemphigoid group diseases to pemphigus group diseases was 1.6. The most common pemphigoid type was bullous pemphigoid (BP, 93.2%). The others were epidermolysis bullosa acquisita (3.1%), pemphigoid gestationis (2.4%), linear IgA disease (1%) and mucous membrane pemphigoid (0.3%). The most common (26.8%) possible trigger of the bullous pemphigoid was gliptin derivative drugs. The most common concomitant diseases with pemphigoid were cardiovascular (27.8%) and neurological diseases (23.7%). Conclusions This study showed that the increased frequency of bullous pemphigoid reversed the pemphigoid/pemphigus ratio in Turkey. Further studies are warranted regarding the reasons for this increase.